{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:39:45Z","timestamp":1789763985065,"version":"4.0.1"},"reference-count":187,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology, Japan","doi-asserted-by":"publisher","award":["23K07279"],"award-info":[{"award-number":["23K07279"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Spinal muscular atrophy (SMA) is a lower motor neuron disease with autosomal recessive inheritance. The first cases of SMA were reported by Werdnig in 1891. Although the phenotypic variation of SMA led to controversy regarding the clinical entity of the disease, the genetic homogeneity of SMA was proved in 1990. Five years later, in 1995, the gene responsible for SMA, SMN1, was identified. Genetic testing of SMN1 has enabled precise epidemiological studies, revealing that SMA occurs in 1 of 10,000 to 20,000 live births and that more than 95% of affected patients are homozygous for SMN1 deletion. In 2016, nusinersen was the first drug approved for treatment of SMA in the United States. Two other drugs were subsequently approved: onasemnogene abeparvovec and risdiplam. Clinical trials with these drugs targeting patients with pre-symptomatic SMA (those who were diagnosed by genetic testing but showed no symptoms) revealed that such patients could achieve the milestones of independent sitting and\/or walking. Following the great success of these trials, population-based newborn screening programs for SMA (more precisely, SMN1-deleted SMA) have been increasingly implemented worldwide. Early detection by newborn screening and early treatment with new drugs are expected to soon become the standards in the field of SMA.<\/jats:p>","DOI":"10.3390\/ijms241511939","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:45:02Z","timestamp":1690332302000},"page":"11939","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":157,"title":["Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6778-4511","authenticated-orcid":false,"given":"Hisahide","family":"Nishio","sequence":"first","affiliation":[{"name":"Faculty of Rehabilitation, Kobe Gakuin University, 518 Arise, Ikawadani-cho, Nishi-ku, Kobe 651-2180, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1311-3448","authenticated-orcid":false,"given":"Emma Tabe Eko","family":"Niba","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular and Biochemical Research, Biomedical Research Core Facilities, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama, Toyonaka 560-8552, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-4222","authenticated-orcid":false,"given":"Kentaro","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Ehime Prefectural Imabari Hospital, 4-5-5 Ishi-cho, Imabari 794-0006, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6468-7185","authenticated-orcid":false,"given":"Yasuhiro","family":"Takeshima","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Awano","sequence":"additional","affiliation":[{"name":"Organization for Research Initiative and Promotion, Research Initiative Center, Tottori University, 86 Nishi-cho, Yonago 683-8503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, Incidence and Carrier Frequency of 5q-Linked Spinal Muscular Atrophy\u2014A Literature Review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal Muscular Atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF01776636","article-title":"Zwei fr\u00fchinfantile heredit\u00e4re F\u00e4lle von progressiver Muskelatrophie unter dem Bilde der Dystrophie, aber anf neurotischer Grundlage","volume":"22","author":"Werdnig","year":"1891","journal-title":"Arch. F\u00fcr Psychiatr. Nervenkrankh."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(80)90847-8","article-title":"Classification of Spinal Muscular Atrophies","volume":"1","author":"Pearn","year":"1980","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/344540a0","article-title":"Genetic Mapping of Chronic Childhood-Onset Spinal Muscular Atrophy to Chromosome 5q11.2-13.3","volume":"344","author":"Brzustowicz","year":"1990","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/345823a0","article-title":"Genetic Homogeneity between Acute and Chronic Forms of Spinal Muscular Atrophy","volume":"345","author":"Gilliam","year":"1990","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/344767a0","article-title":"Gene for Chronic Proximal Spinal Muscular Atrophies Maps to Chromosome 5q","volume":"344","author":"Melki","year":"1990","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0140-6736(90)91803-I","article-title":"Mapping of Acute (Type I) Spinal Muscular Atrophy to Chromosome 5q12-Q14. The French Spinal Muscular Atrophy Investigators","volume":"336","author":"Melki","year":"1990","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1090-3798(99)80012-9","article-title":"Very Severe Spinal Muscular Atrophy (SMA Type 0): An Expanding Clinical Phenotype","volume":"3","author":"Dubowitz","year":"1999","journal-title":"Eur. J. Paediatr. Neurol. EJPN Off. J. Eur. Paediatr. Neurol. Soc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(95)92881-2","article-title":"SMN Gene Deletions in Adult-Onset Spinal Muscular Atrophy","volume":"346","author":"Clermont","year":"1995","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.24497","article-title":"Spinal Muscular Atrophy: Diagnosis and Management in a New Therapeutic Era","volume":"51","author":"Arnold","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and Characterization of a Spinal Muscular Atrophy-Determining Gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"ref_13","unstructured":"Gamstorp, I., and Sarnat, H.B. (1984). Progressive Spinal Muscular Atrophie, Raven Press."},{"key":"ref_14","unstructured":"Sumner, C.J., Paushkin, S., and Ko, C.-P. (2017). Spinal Muscular Atrophy, Academic Press."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100346","DOI":"10.1016\/j.xcrm.2021.100346","article-title":"Spinal Muscular Atrophy: From Approved Therapies to Future Therapeutic Targets for Personalized Medicine","volume":"2","author":"Chaytow","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF01668496","article-title":"Ueber chronische spinale Muskelatrophie im Kindesalter, auf famili\u00e4rer Basis","volume":"3","author":"Hoffmann","year":"1893","journal-title":"Dtsch. Z. F\u00fcr Nervenheilkd."},{"key":"ref_17","first-page":"361","article-title":"A Case of Progressive Muscular Atrophy in a Child, with a Spinal Lesion","volume":"Volume 1","author":"Gibson","year":"1893","journal-title":"Edinburgh Hospital Reports: The Supervision of the Editorial Committee of the Royal Infirmary Royal Hospital for Sick Children"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/brain\/25.1.85","article-title":"A Case of Congenital Spinal Muscular Atrophy (Family Type), and a Case of Haemorrhage into the Spinal Cord at Birth, Giving Similar Symptoms","volume":"25","author":"Beevor","year":"1902","journal-title":"Brain"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.nmd.2008.10.004","article-title":"Ramblings in the History of Spinal Muscular Atrophy","volume":"19","author":"Dubowitz","year":"2009","journal-title":"Neuromuscul. Disord. NMD"},{"key":"ref_20","first-page":"3","article-title":"Paralysie Flasque de Quatre Membres et Des Muscles Du Tronc (Sauf Le Diaphragme) Chez Un Nouveau-Ne","volume":"1","author":"Sylvestre","year":"1899","journal-title":"Bull. Soc. Pediatr. Paris"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000221507","article-title":"Ueber Allgemeine Und Localisierte Atonie Der Muskulatur (Myatonie) Im Fr\u00fchen Kindesalter.: Vorl\u00e4ufige Mitteilung","volume":"8","author":"Oppenheim","year":"1900","journal-title":"Monatsschrift F\u00fcr Psychiatr. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/archpedi.1945.02020170030006","article-title":"Amyotonia congenita (oppenheim): Report of five cases with necropsy; discussion of the relationship between amyotonia congenita, werdnig-hoffmann disease, neonatal poliomyelitis and muscular dystrophy","volume":"69","author":"Burdick","year":"1945","journal-title":"Am. J. Dis. Child."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archneurpsyc.1950.02310200026003","article-title":"Course and symptoms of progressive infantile muscular atrophy: A Follow-Up Study of One Hundred and Twelve Cases in Denmark","volume":"63","author":"Brandt","year":"1950","journal-title":"Arch. Neurol. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/brain\/50.3-4.652","article-title":"The anatomical identity of the werdnig-hoffmann and oppenheim forms of infantile muscular atrophy","volume":"50","author":"Greenfield","year":"1927","journal-title":"Brain"},{"key":"ref_25","first-page":"301","article-title":"The Amyotonia Congenita Syndrome","volume":"50","author":"Walton","year":"1957","journal-title":"Proc. R. Soc. Med."},{"key":"ref_26","unstructured":"Gamstorp, I., and Sarnat, H. (1984). Progressive Spinal Muscular Atrophy, Raven Press."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","article-title":"Spinal Muscular Atrophies","volume":"62","author":"Darras","year":"2015","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/brain\/87.4.707","article-title":"Infantile muscular atrophy. a prospective study with particular reference to a slowly progressive variety","volume":"87","author":"Dubowitz","year":"1964","journal-title":"Brain J. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/archneurpsyc.1956.02330230050005","article-title":"Heredofamilial Juvenile Muscular Atrophy Simulating Muscular Dystrophy","volume":"75","author":"Kugelberg","year":"1956","journal-title":"AMA Arch. Neurol. Psychiatry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.nmd.2005.07.005","article-title":"134th ENMC International Workshop: Outcome Measures and Treatment of Spinal Muscular Atrophy, 11-13 February 2005, Naarden, The Netherlands","volume":"15","author":"Bertini","year":"2005","journal-title":"Neuromuscul. Disord. NMD"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","article-title":"A Collaborative Study on the Natural History of Childhood and Juvenile Onset Proximal Spinal Muscular Atrophy (Type II and III SMA): 569 Patients","volume":"146","author":"Zerres","year":"1997","journal-title":"J. Neurol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","article-title":"209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7\u20139 November 2014, Heemskerk, The Netherlands","volume":"25","author":"Finkel","year":"2015","journal-title":"Neuromuscul. Disord. NMD"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1090-3798(99)80015-4","article-title":"Prenatal Onset Spinal Muscular Atrophy","volume":"3","author":"MacLeod","year":"1999","journal-title":"Eur. J. Paediatr. Neurol. EJPN Off. J. Eur. Paediatr. Neurol. Soc."},{"key":"ref_34","unstructured":"Sumner, C.J., Paushkin, S., and Ko, C.-P. (2017). Spinal Muscular Atrophy, Academic Press."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0092-8674(95)90461-1","article-title":"The Gene for Neuronal Apoptosis Inhibitory Protein Is Partially Deleted in Individuals with Spinal Muscular Atrophy","volume":"80","author":"Roy","year":"1995","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Blatnik, A.J., McGovern, V.L., and Burghes, A.H.M. (2021). What Genetics Has Told Us and How It Can Inform Future Experiments for Spinal Muscular Atrophy, a Perspective. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168494"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/geno.1996.0147","article-title":"Structure and Organization of the Human Survival Motor Neurone (SMN) Gene","volume":"32","author":"Lefebvre","year":"1996","journal-title":"Genomics"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","article-title":"The Survival Motor Neuron Protein in Spinal Muscular Atrophy","volume":"6","author":"Coovert","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between Severity and SMN Protein Level in Spinal Muscular Atrophy","volume":"16","author":"Lefebvre","year":"1997","journal-title":"Nat. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1002\/j.1460-2075.1996.tb00725.x","article-title":"A Novel Nuclear Structure Containing the Survival of Motor Neurons Protein","volume":"15","author":"Dreyfuss","year":"1996","journal-title":"EMBO J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.tcb.2004.03.010","article-title":"Why Do Cells Need an Assembly Machine for RNA-Protein Complexes?","volume":"14","author":"Yong","year":"2004","journal-title":"Trends Cell Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/sj.embor.7400941","article-title":"Chaperoning Ribonucleoprotein Biogenesis in Health and Disease","volume":"8","author":"Pellizzoni","year":"2007","journal-title":"EMBO Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/hmg\/7.12.1927","article-title":"The Distribution of SMN Protein Complex in Human Fetal Tissues and Its Alteration in Spinal Muscular Atrophy","volume":"7","author":"Burlet","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1172\/JCI124120","article-title":"Age-Dependent SMN Expression in Disease-Relevant Tissue and Implications for SMA Treatment","volume":"129","author":"Ramos","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0092-8674(00)80367-0","article-title":"The Spinal Muscular Atrophy Disease Gene Product, SMN, and Its Associated Protein SIP1 Are in a Complex with Spliceosomal SnRNP Proteins","volume":"90","author":"Liu","year":"1997","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0092-8674(00)80368-2","article-title":"The SMN-SIP1 Complex Has an Essential Role in Spliceosomal SnRNP Biogenesis","volume":"90","author":"Fischer","year":"1997","journal-title":"Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.neuron.2005.12.001","article-title":"Spinal Muscular Atrophy: A Deficiency in a Ubiquitous Protein; a Motor Neuron-Specific Disease","volume":"48","author":"Monani","year":"2005","journal-title":"Neuron"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrn2670","article-title":"Spinal Muscular Atrophy: Why Do Low Levels of Survival Motor Neuron Protein Make Motor Neurons Sick?","volume":"10","author":"Burghes","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1101\/gad.908401","article-title":"Coilin Forms the Bridge between Cajal Bodies and SMN, the Spinal Muscular Atrophy Protein","volume":"15","author":"Hebert","year":"2001","journal-title":"Genes Dev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1093\/hmg\/8.13.2351","article-title":"Essential Role for the Tudor Domain of SMN in Spliceosomal U SnRNP Assembly: Implications for Spinal Muscular Atrophy","volume":"8","author":"Raker","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/83014","article-title":"SMN Tudor Domain Structure and Its Interaction with the Sm Proteins","volume":"8","author":"Selenko","year":"2001","journal-title":"Nat. Struct. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.str.2012.08.024","article-title":"The Survival Motor Neuron Protein Forms Soluble Glycine Zipper Oligomers","volume":"20","author":"Martin","year":"2012","journal-title":"Structure"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbagrm.2016.12.008","article-title":"Diverse Role of Survival Motor Neuron Protein","volume":"1860","author":"Singh","year":"2017","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1007\/s00018-018-2849-1","article-title":"The Role of Survival Motor Neuron Protein (SMN) in Protein Homeostasis","volume":"75","author":"Chaytow","year":"2018","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1083\/jcb.200304128","article-title":"Smn, the Spinal Muscular Atrophy-Determining Gene Product, Modulates Axon Growth and Localization of Beta-Actin MRNA in Growth Cones of Motoneurons","volume":"163","author":"Rossoll","year":"2003","journal-title":"J. Cell Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.brainres.2012.01.044","article-title":"Spinal Muscular Atrophy: The Role of SMN in Axonal MRNA Regulation","volume":"1462","author":"Fallini","year":"2012","journal-title":"Brain Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","article-title":"Reduced SMN Protein Impairs Maturation of the Neuromuscular Junctions in Mouse Models of Spinal Muscular Atrophy","volume":"17","author":"Kariya","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ajhg.2016.07.014","article-title":"The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype","volume":"99","author":"Hosseinibarkooie","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ajhg.2017.01.005","article-title":"Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis","volume":"100","author":"Riessland","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.neuron.2023.02.004","article-title":"A Spinal Muscular Atrophy Modifier Implicates the SMN Protein in SNARE Complex Assembly at Neuromuscular Synapses","volume":"111","author":"Kim","year":"2023","journal-title":"Neuron"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/bpa.12071","article-title":"Spinal Muscular Atrophy: New Findings for an Old Pathology","volume":"23","author":"Bottai","year":"2013","journal-title":"Brain Pathol. Zur. Switz."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI131989","article-title":"Muscle-Specific SMN Reduction Reveals Motor Neuron-Independent Disease in Spinal Muscular Atrophy Models","volume":"130","author":"Kim","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e202201457","DOI":"10.26508\/lsa.202201457","article-title":"SMN Promotes Mitochondrial Metabolic Maturation during Myogenesis by Regulating the MYOD-MiRNA Axis","volume":"6","author":"Ikenaka","year":"2023","journal-title":"Life Sci. Alliance"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/379349a0","article-title":"Suppression of Apoptosis in Mammalian Cells by NAIP and a Related Family of IAP Genes","volume":"379","author":"Liston","year":"1996","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/nm0997-997","article-title":"Elevation of Neuronal Expression of NAIP Reduces Ischemic Damage in the Rat Hippocampus","volume":"3","author":"Xu","year":"1997","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A Single Nucleotide Difference That Alters Splicing Patterns Distinguishes the SMA Gene SMN1 from the Copy Gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/71709","article-title":"A Mouse Model for Spinal Muscular Atrophy","volume":"24","author":"Chang","year":"2000","journal-title":"Nat. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/hmg\/9.3.333","article-title":"The Human Centromeric Survival Motor Neuron Gene (SMN2) Rescues Embryonic Lethality in Smn\u2212\/\u2212 Mice and Results in a Mouse with Spinal Muscular Atrophy","volume":"9","author":"Monani","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A Single Nucleotide in the SMN Gene Regulates Splicing and Is Responsible for Spinal Muscular Atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Crawford, T.O., Paushkin, S.V., Kobayashi, D.T., Forrest, S.J., Joyce, C.L., Finkel, R.S., Kaufmann, P., Swoboda, K.J., Tiziano, D., and Lomastro, R. (2012). Evaluation of SMN Protein, Transcript, and Copy Number in the Biomarkers for Spinal Muscular Atrophy (BforSMA) Clinical Study. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033572"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Wadman, R.I., Stam, M., Jansen, M.D., van der Weegen, Y., Wijngaarde, C.A., Harschnitz, O., Sodaar, P., Braun, K.P.J., Dooijes, D., and Lemmink, H.H. (2016). A Comparative Study of SMN Protein and MRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy Controls. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0167087"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2353\/ajpath.2007.070399","article-title":"Refined Characterization of the Expression and Stability of the SMN Gene Products","volume":"171","author":"Vitte","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1101\/gad.1884910","article-title":"A Degron Created by SMN2 Exon 7 Skipping Is a Principal Contributor to Spinal Muscular Atrophy Severity","volume":"24","author":"Cho","year":"2010","journal-title":"Genes Dev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1093\/hmg\/ddq425","article-title":"A Feedback Loop Regulates Splicing of the Spinal Muscular Atrophy-Modifying Gene, SMN2","volume":"19","author":"Jodelka","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/ng854","article-title":"Disruption of an SF2\/ASF-Dependent Exonic Splicing Enhancer in SMN2 Causes Spinal Muscular Atrophy in the Absence of SMN1","volume":"30","author":"Cartegni","year":"2002","journal-title":"Nat. Genet."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ng1207","article-title":"A Negative Element in SMN2 Exon 7 Inhibits Splicing in Spinal Muscular Atrophy","volume":"34","author":"Kashima","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1261\/rna.1273209","article-title":"Differential 3\u2032 Splice Site Recognition of SMN1 and SMN2 Transcripts by U2AF and U2 SnRNP","volume":"15","author":"Bonnal","year":"2009","journal-title":"RNA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1086\/498853","article-title":"Determinants of Exon 7 Splicing in the Spinal Muscular Atrophy Genes, SMN1 and SMN2","volume":"78","author":"Cartegni","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ng0598-63","article-title":"SMN Oligomerization Defect Correlates with Spinal Muscular Atrophy Severity","volume":"19","author":"Lorson","year":"1998","journal-title":"Nat. Genet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1128\/MCB.01262-08","article-title":"Regulation of SMN Protein Stability","volume":"29","author":"Burnett","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Niba, E.T.E., Nishio, H., Wijaya, Y.O.S., Ar Rochmah, M., Takarada, T., Takeuchi, A., Kimizu, T., Okamoto, K., Saito, T., and Awano, H. (2022). Stability and Oligomerization of Mutated SMN Protein Determine Clinical Severity of Spinal Muscular Atrophy. Genes, 13.","DOI":"10.3390\/genes13020205"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/hmg\/5.2.257","article-title":"Molecular Analysis of the SMN and NAIP Genes in Spanish Spinal Muscular Atrophy (SMA) Families and Correlation between Number of Copies of CBCD541 and SMA Phenotype","volume":"5","author":"Velasco","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1086\/515465","article-title":"Identification of Proximal Spinal Muscular Atrophy Carriers and Patients by Analysis of SMNT and SMNC Gene Copy Number","volume":"60","author":"McAndrew","year":"1997","journal-title":"Am. J. Hum. Genet."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative Analyses of SMN1 and SMN2 Based on Real-Time LightCycler PCR: Fast and Highly Reliable Carrier Testing and Prediction of Severity of Spinal Muscular Atrophy","volume":"70","author":"Schwarzer","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00415-002-0811-4","article-title":"Correlation between SMN2 Copy Number and Clinical Phenotype of Spinal Muscular Atrophy: Three SMN2 Copies Fail to Rescue Some Patients from the Disease Severity","volume":"249","author":"Harada","year":"2002","journal-title":"J. Neurol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.braindev.2013.11.009","article-title":"Intragenic Mutations in SMN1 May Contribute More Significantly to Clinical Severity than SMN2 Copy Numbers in Some Spinal Muscular Atrophy (SMA) Patients","volume":"36","author":"Yamamoto","year":"2014","journal-title":"Brain Dev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1212\/NXG.0000000000000505","article-title":"Intragenic Variants in the SMN1 Gene Determine the Clinical Phenotype in 5q Spinal Muscular Atrophy","volume":"6","author":"Matsui","year":"2020","journal-title":"Neurol. Genet."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pediatrneurol.2016.01.019","article-title":"Telomeric Region of the Spinal Muscular Atrophy Locus Is Susceptible to Structural Variations","volume":"58","author":"Noguchi","year":"2016","journal-title":"Pediatr. Neurol."},{"key":"ref_89","first-page":"834","article-title":"Apparent Gene Conversions Involving the SMN Gene in the Region of the Spinal Muscular Atrophy Locus on Chromosome 5","volume":"59","author":"Grootscholten","year":"1996","journal-title":"Am. J. Hum. Genet."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.braindev.2020.09.005","article-title":"Clinical Phenotypes of Spinal Muscular Atrophy Patients with Hybrid SMN Gene","volume":"43","author":"Niba","year":"2021","journal-title":"Brain Dev."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1086\/513886","article-title":"Genomic Variation and Gene Conversion in Spinal Muscular Atrophy: Implications for Disease Process and Clinical Phenotype","volume":"61","author":"Campbell","year":"1997","journal-title":"Am. J. Hum. Genet."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1086\/513913","article-title":"When Is a Deletion Not a Deletion? When It Is Converted","volume":"61","author":"Burghes","year":"1997","journal-title":"Am. J. Hum. Genet."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s004390100473","article-title":"SMN Gene Duplication and the Emergence of the SMN2 Gene Occurred in Distinct Hominids: SMN2 Is Unique to Homo Sapiens","volume":"108","author":"Rochette","year":"2001","journal-title":"Hum. Genet."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41559-016-0069","article-title":"The Evolution and Population Diversity of Human-Specific Segmental Duplications","volume":"1","author":"Dennis","year":"2017","journal-title":"Nat. Ecol. Evol."},{"key":"ref_95","first-page":"346","article-title":"SMN2 and NAIP Gene Dosages in Vietnamese Patients with Spinal Muscular Atrophy","volume":"50","author":"Tran","year":"2008","journal-title":"Pediatr. Int. Off. J. Jpn. Pediatr. Soc."},{"key":"ref_96","first-page":"93","article-title":"Determination of SMN1 and SMN2 Copy Numbers in a Korean Population Using Multiplex Ligation-Dependent Probe Amplification","volume":"30","author":"Yoon","year":"2010","journal-title":"Korean J. Lab. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.ejhg.5200957","article-title":"Inverse Correlation between SMN1 and SMN2 Copy Numbers: Evidence for Gene Conversion from SMN2 to SMN1","volume":"11","author":"Ogino","year":"2003","journal-title":"Eur. J. Hum. Genet. EJHG"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ana.24114","article-title":"Genetics of Low Spinal Muscular Atrophy Carrier Frequency in Sub-Saharan Africa","volume":"75","author":"Hendrickson","year":"2014","journal-title":"Ann. Neurol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3233\/JND-190399","article-title":"Spinal Muscular Atrophy (SMA) Subtype Concordance in Siblings: Findings from the Cure SMA Cohort","volume":"7","author":"Jones","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1126\/science.1155085","article-title":"Plastin 3 Is a Protective Modifier of Autosomal Recessive Spinal Muscular Atrophy","volume":"320","author":"Oprea","year":"2008","journal-title":"Science"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1523\/JNEUROSCI.5808-11.2012","article-title":"Survival Motor Neuron Affects Plastin 3 Protein Levels Leading to Motor Defects","volume":"32","author":"Hao","year":"2012","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nsb887","article-title":"Correction of Disease-Associated Exon Skipping by Synthetic Exon-Specific Activators","volume":"10","author":"Cartegni","year":"2003","journal-title":"Nat. Struct. Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1073\/pnas.0633863100","article-title":"Bifunctional Antisense Oligonucleotides Provide a Trans-Acting Splicing Enhancer That Stimulates SMN2 Gene Expression in Patient Fibroblasts","volume":"100","author":"Skordis","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"23271","DOI":"10.1074\/jbc.M200851200","article-title":"Identification of a Cis-Acting Element for the Regulation of SMN Exon 7 Splicing","volume":"277","author":"Miyajima","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","article-title":"Splicing of a Critical Exon of Human Survival Motor Neuron Is Regulated by a Unique Silencer Element Located in the Last Intron","volume":"26","author":"Singh","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense Masking of an HnRNP A1\/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1083\/jcb.201207087","article-title":"Antisense-Based Therapy for the Treatment of Spinal Muscular Atrophy","volume":"199","author":"Rigo","year":"2012","journal-title":"J. Cell Biol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1172\/JCI22922","article-title":"Lentivector-Mediated SMN Replacement in a Mouse Model of Spinal Muscular Atrophy","volume":"114","author":"Azzouz","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 Preferentially Targets Neonatal Neurons and Adult Astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the Spinal Muscular Atrophy Phenotype in a Mouse Model by Early Postnatal Delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_112","unstructured":"Sumner, C.J., Paushkin, S., and Ko, C.-P. (2017). Spinal Muscular Atrophy, Academic Press."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/hmg\/10.24.2841","article-title":"Aclarubicin Treatment Restores SMN Levels to Cells Derived from Type I Spinal Muscular Atrophy Patients","volume":"10","author":"Andreassi","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"5ra12","DOI":"10.1126\/scitranslmed.3000208","article-title":"Tetracyclines That Promote SMN2 Exon 7 Splicing as Therapeutics for Spinal Muscular Atrophy","volume":"1","author":"Hastings","year":"2009","journal-title":"Sci. Transl. Med."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Wee, C.D., Havens, M.A., Jodelka, F.M., and Hastings, M.L. (2014). Targeting SR Proteins Improves SMN Expression in Spinal Muscular Atrophy Cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115205"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1126\/science.1250127","article-title":"Motor Neuron Disease. SMN2 Splicing Modifiers Improve Motor Function and Longevity in Mice with Spinal Muscular Atrophy","volume":"345","author":"Naryshkin","year":"2014","journal-title":"Science"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","article-title":"Valproic Acid Increases the SMN2 Protein Level: A Well-Known Drug as a Potential Therapy for Spinal Muscular Atrophy","volume":"12","author":"Brichta","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10743","article-title":"Valproic Acid Increases SMN Levels in Spinal Muscular Atrophy Patient Cells","volume":"54","author":"Sumner","year":"2003","journal-title":"Ann. Neurol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/01.wnl.0000231139.26253.d0","article-title":"Valproate May Improve Strength and Function in Patients with Type III\/IV Spinal Muscle Atrophy","volume":"67","author":"Weihl","year":"2006","journal-title":"Neurology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ana.20836","article-title":"In Vivo Activation of SMN in Spinal Muscular Atrophy Carriers and Patients Treated with Valproate","volume":"59","author":"Brichta","year":"2006","journal-title":"Ann. Neurol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Swoboda, K.J., Scott, C.B., Reyna, S.P., Prior, T.W., LaSalle, B., Sorenson, S.L., Wood, J., Acsadi, G., Crawford, T.O., and Kissel, J.T. (2009). Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005268"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Swoboda, K.J., Scott, C.B., Crawford, T.O., Simard, L.R., Reyna, S.P., Krosschell, K.J., Acsadi, G., Elsheik, B., Schroth, M.K., and D\u2019Anjou, G. (2010). SMA CARNI-VAL Trial Part I: Double-Blind, Randomized, Placebo-Controlled Trial of L-Carnitine and Valproic Acid in Spinal Muscular Atrophy. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012140"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Kissel, J.T., Scott, C.B., Reyna, S.P., Crawford, T.O., Simard, L.R., Krosschell, K.J., Acsadi, G., Elsheik, B., Schroth, M.K., and D\u2019Anjou, G. (2011). SMA CARNIVAL TRIAL PART II: A Prospective, Single-Armed Trial of L-Carnitine and Valproic Acid in Ambulatory Children with Spinal Muscular Atrophy. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0021296"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/hmg\/dds437","article-title":"VPA Response in SMA Is Suppressed by the Fatty Acid Translocase CD36","volume":"22","author":"Garbes","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/ejhg.2011.89","article-title":"Treatment of Spinal Muscular Atrophy Cells with Drugs That Upregulate SMN Expression Reveals Inter- and Intra-Patient Variability","volume":"19","author":"Caselles","year":"2011","journal-title":"Eur. J. Hum. Genet. EJHG"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1042\/cs0830615","article-title":"Salbutamol, a Beta 2-Adrenoceptor Agonist, Increases Skeletal Muscle Strength in Young Men","volume":"83","author":"Martineau","year":"1992","journal-title":"Clin. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.57.8.1434","article-title":"Randomized, Double-Blind, Placebo-Controlled Trial of Albuterol in Facioscapulohumeral Dystrophy","volume":"57","author":"Kissel","year":"2001","journal-title":"Neurology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/WNL.59.4.609","article-title":"Pilot Trial of Albuterol in Spinal Muscular Atrophy","volume":"59","author":"Kinali","year":"2002","journal-title":"Neurology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.nmd.2008.05.004","article-title":"Daily Salbutamol in Young Patients with SMA Type II","volume":"18","author":"Pane","year":"2008","journal-title":"Neuromuscul. Disord. NMD"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jmedgenet-2018-105482","article-title":"Longitudinal Evaluation of SMN Levels as Biomarker for Spinal Muscular Atrophy: Results of a Phase IIb Double-Blind Study of Salbutamol","volume":"56","author":"Tiziano","year":"2019","journal-title":"J. Med. Genet."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/jmg.2007.051177","article-title":"Salbutamol Increases SMN MRNA and Protein Levels in Spinal Muscular Atrophy Cells","volume":"45","author":"Angelozzi","year":"2008","journal-title":"J. Med. Genet."},{"key":"ref_132","first-page":"351","article-title":"Salbutamol Inhibits Ubiquitin-Mediated Survival Motor Neuron Protein Degradation in Spinal Muscular Atrophy Cells","volume":"4","author":"Harahap","year":"2015","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_133","unstructured":"(2023, June 26). SPINRAZA (Nusinersen) Injection, for Intrathecal Use. Food and Drug Administration (.gov), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/209531lbl.pdf."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/gt.2017.34","article-title":"How the Discovery of ISS-N1 Led to the First Medical Therapy for Spinal Muscular Atrophy","volume":"24","author":"Singh","year":"2017","journal-title":"Gene Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen Initiated in Infants during the Presymptomatic Stage of Spinal Muscular Atrophy: Interim Efficacy and Safety Results from the Phase 2 NURTURE Study","volume":"29","author":"Bertini","year":"2019","journal-title":"Neuromuscul. Disord. NMD"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1007\/s12035-017-0831-9","article-title":"Time Is Motor Neuron: Therapeutic Window and Its Correlation with Pathogenetic Mechanisms in Spinal Muscular Atrophy","volume":"55","author":"Govoni","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_139","unstructured":"(2023, June 26). Package Insert\u2014ZOLGENSMA. Food and Drug Administration (.gov), Available online: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/zolgensma.pdf."},{"key":"ref_140","unstructured":"Stroud, C., and Bain, L. (2019). Advancing Gene-Targeted Therapies for Central Nervous System Disorders: Proceedings of a Workshop, National Academies Press (US). The National Academies Collection: Reports Funded by National Institutes of Health."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","article-title":"Impact of Age and Motor Function in a Phase 1\/2A Study of Infants with SMA Type 1 Receiving Single-Dose Gene Replacement Therapy","volume":"98","author":"Lowes","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene Abeparvovec for Presymptomatic Infants with Two Copies of SMN2 at Risk for Spinal Muscular Atrophy Type 1: The Phase III SPR1NT Trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene Abeparvovec for Presymptomatic Infants with Three Copies of SMN2 at Risk for Spinal Muscular Atrophy: The Phase III SPR1NT Trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"ref_146","unstructured":"(2023, June 26). Risdiplam: Prescription Information. Available online: https:\/\/www.gene.com\/download\/pdf\/evrysdi_prescribing.pdf."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2633105520973985","DOI":"10.1177\/2633105520973985","article-title":"The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy","volume":"15","author":"Singh","year":"2020","journal-title":"Neurosci. Insights"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"7167","DOI":"10.1039\/D0CS00560F","article-title":"Small Molecule Recognition of Disease-Relevant RNA Structures","volume":"49","author":"Meyer","year":"2020","journal-title":"Chem. Soc. Rev."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-3-319-89689-2_2","article-title":"Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes","volume":"20","author":"Singh","year":"2018","journal-title":"Adv. Neurobiol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41467-017-01559-4","article-title":"Binding to SMN2 Pre-MRNA-Protein Complex Elicits Specificity for Small Molecule Splicing Modifiers","volume":"8","author":"Sivaramakrishnan","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_151","first-page":"E4604","article-title":"Mechanistic Studies of a Small-Molecule Modulator of SMN2 Splicing","volume":"115","author":"Wang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in Type 1 Spinal Muscular Atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls","volume":"385","author":"Darras","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","article-title":"Safety and Efficacy of Risdiplam in Patients with Type 1 Spinal Muscular Atrophy (FIREFISH Part 2): Secondary Analyses from an Open-Label Trial","volume":"21","author":"Masson","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.nmd.2022.07.199","article-title":"SUNFISH Parts 1 and 2: 3-Year Efficacy and Safety of Risdiplam in Types 2 and 3 Spinal Muscular Atrophy (SMA)","volume":"32","author":"Day","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and Efficacy of Once-Daily Risdiplam in Type 2 and Non-Ambulant Type 3 Spinal Muscular Atrophy (SUNFISH Part 2): A Phase 3, Double-Blind, Randomised, Placebo-Controlled Trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","article-title":"Two-Year Efficacy and Safety of Risdiplam in Patients with Type 2 or Non-Ambulant Type 3 Spinal Muscular Atrophy (SMA)","volume":"270","author":"Oskoui","year":"2023","journal-title":"J. Neurol."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Finkel, R.S., Farrar, M.A., Vlodavets, D., Servais, L., Zanoteli, E., Al-Muhaizea, M., Nelson, L., Prufer, A., Wang, Y., and Fisher, C. (2022, January 13\u201316). RAINBOWFISH: Preliminary Efficacy and Safety Data in Risdiplam-Treated Infants with Presymptomatic SMA (P17-5.003). Proceedings of the Muscular Dystrophy Association Clinical and Scientific Conference, Nashville, TN, USA.","DOI":"10.1212\/WNL.98.18_supplement.1636"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nmd.2019.11.002","article-title":"244th ENMC International Workshop: Newborn Screening in Spinal Muscular Atrophy 10\u201312 May 2019, Hoofdorp, The Netherlands","volume":"30","author":"Dangouloff","year":"2020","journal-title":"Neuromuscul. Disord. NMD"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","article-title":"Newborn Screening Programs for Spinal Muscular Atrophy Worldwide: Where We Stand and Where to Go","volume":"31","author":"Dangouloff","year":"2021","journal-title":"Neuromuscul. Disord. NMD"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.pediatrneurol.2015.06.002","article-title":"Delay in Diagnosis of Spinal Muscular Atrophy: A Systematic Literature Review","volume":"53","author":"Lin","year":"2015","journal-title":"Pediatr. Neurol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S2352-4642(22)00342-X","article-title":"Newborn Screening for Spinal Muscular Atrophy in Australia: A Non-Randomised Cohort Study","volume":"7","author":"Kariyawasam","year":"2023","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Noguchi, Y., Bo, R., Nishio, H., Matsumoto, H., Matsui, K., Yano, Y., Sugawara, M., Ueda, G., Wijaya, Y.O.S., and Niba, E.T.E. (2022). PCR-Based Screening of Spinal Muscular Atrophy for Newborn Infants in Hyogo Prefecture, Japan. Genes, 13.","DOI":"10.3390\/genes13112110"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening","volume":"5","author":"Glascock","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JND-190468","article-title":"Revised Recommendations for the Treatment of Infants Diagnosed with Spinal Muscular Atrophy Via Newborn Screening Who Have 4 Copies of SMN2","volume":"7","author":"Glascock","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-200475","article-title":"Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening\u2014Opportunity or Burden?","volume":"7","author":"Vill","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13023-021-01783-8","article-title":"Newborn Screening for Spinal Muscular Atrophy in Germany: Clinical Results after 2 Years","volume":"16","author":"Vill","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"100742","DOI":"10.1016\/j.eclinm.2021.100742","article-title":"\u201cWe Needed This\u201d: Perspectives of Parents and Healthcare Professionals Involved in a Pilot Newborn Screening Program for Spinal Muscular Atrophy","volume":"33","author":"Kariyawasam","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Lee, T., Tokunaga, S., Taniguchi, N., Fujino, T., Saito, M., Shimomura, H., and Takeshima, Y. (2021). Views of the General Population on Newborn Screening for Spinal Muscular Atrophy in Japan. Children, 8.","DOI":"10.3390\/children8080694"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ana.24864","article-title":"Emerging Therapies and Challenges in Spinal Muscular Atrophy","volume":"81","author":"Farrar","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1172\/JCI121658","article-title":"Two Breakthrough Gene-Targeted Treatments for Spinal Muscular Atrophy: Challenges Remain","volume":"128","author":"Sumner","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JND-190424","article-title":"Advances in Treatment of Spinal Muscular Atrophy\u2014New Phenotypes, New Challenges, New Implications for Care","volume":"7","author":"Schorling","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.nmd.2021.08.009","article-title":"Spinal Muscular Atrophy: From Rags to Riches","volume":"31","author":"Mercuri","year":"2021","journal-title":"Neuromuscul. Disord. NMD"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Day, J.W., Howell, K., Place, A., Long, K., Rossello, J., Kertesz, N., and Nomikos, G. (2022). Advances and Limitations for the Treatment of Spinal Muscular Atrophy. BMC Pediatr., 22.","DOI":"10.1186\/s12887-022-03671-x"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1212\/WNL.0000000000009914","article-title":"Nusinersen in Adult Patients with Spinal Muscular Atrophy: Observations from a Single Center","volume":"95","author":"Visser","year":"2020","journal-title":"Neurology"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/ene.14567","article-title":"Sometimes They Come Back: New and Old Spinal Muscular Atrophy Adults in the Era of Nusinersen","volume":"28","author":"Sansone","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Okamoto, K., Nishio, H., Motoki, T., Jogamoto, T., Aibara, K., Kondo, Y., Kawamura, K., Konishi, Y., Tokorodani, C., and Nishiuchi, R. (2022). Changes in the Incidence of Infantile Spinal Muscular Atrophy in Shikoku, Japan between 2011 and 2020. Int. J. Neonatal Screen., 8.","DOI":"10.3390\/ijns8040052"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/apa.16568","article-title":"How Children and Caregivers Viewed the Change from Nusinersen to Risdiplam for Treating Spinal Muscular Atrophy","volume":"112","author":"Agosto","year":"2023","journal-title":"Acta Paediatr."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13023-020-01593-4","article-title":"Do We Always Need to Treat Patients with Spinal Muscular Atrophy? A Personal View and Experience","volume":"16","author":"Agosto","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_180","first-page":"000574","article-title":"Sequential Treatment with Nusinersen and Risdiplam in a Paediatric Patient with Spinal Muscular Atrophy: A Case Report","volume":"3","author":"Sevilla","year":"2022","journal-title":"Examines Phys. Med. Rehabil. Open Access"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.2147\/IJGM.S369021","article-title":"Experience and Perspectives in the US on the Evolving Treatment Landscape in Spinal Muscular Atrophy","volume":"15","author":"Elman","year":"2022","journal-title":"Int. J. Gen. Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1002\/mus.27648","article-title":"Novel Use of Nusinersen as a Therapeutic Bridge to Onasemnogene Abeparvovec-Xioi in a Premature Neonate with Type 1 Spinal Muscular Atrophy","volume":"66","author":"Ferrante","year":"2022","journal-title":"Muscle Nerve"},{"key":"ref_183","first-page":"117","article-title":"Switching Therapies: Safety Profile of Onasemnogene Abeparvovec-Xioi in a SMA1 Patient Previously Treated with Risdiplam","volume":"41","author":"Tosi","year":"2022","journal-title":"Acta Myol. Myopathies Cardiomyopathies Off. J. Mediterr. Soc. Myol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/mus.27034","article-title":"Combination Molecular Therapies for Type 1 Spinal Muscular Atrophy","volume":"62","author":"Harada","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/jnc.14935","article-title":"Combined Treatment with the Histone Deacetylase Inhibitor LBH589 and a Splice-Switch Antisense Oligonucleotide Enhances SMN2 Splicing and SMN Expression in Spinal Muscular Atrophy Cells","volume":"153","author":"Pagliarini","year":"2020","journal-title":"J. Neurochem."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.cell.2022.04.031","article-title":"Counteracting Chromatin Effects of a Splicing-Correcting Antisense Oligonucleotide Improves Its Therapeutic Efficacy in Spinal Muscular Atrophy","volume":"185","author":"Marasco","year":"2022","journal-title":"Cell"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ymthe.2021.04.003","article-title":"Novel Genome-Editing-Based Approaches to Treat Motor Neuron Diseases: Promises and Challenges","volume":"30","author":"Miccio","year":"2022","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/15\/11939\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:19:01Z","timestamp":1760127541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/15\/11939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":187,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["ijms241511939"],"URL":"https:\/\/doi.org\/10.3390\/ijms241511939","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]}}}